Table 3 Time to next line of treatment or death (months).
From: Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period
Time Period | |||||
|---|---|---|---|---|---|
LOT | 1980–89 | 1990–99 | 2000–09 | 2010–20 | p-value |
1st to 2nd | 15.4 (11.8–19.4) | 16.5 (14.3–19.1) | 22.9 (19.1–26.6) | 23.9 (20.1–27.2) | 0.0003 |
2nd to 3rd | 9.4 (5.5–22.2) | 11.4 (9.0–14.0) | 12.1 (10.8–14.5) | 8.1 (6.1–10.5) | 0.0003 |
3rd to 4th | 11.8 (9.7–28.1) | 9.1 (5.7–17.4) | 6.7 (5.5–8.9) | 7.2 (5.7–9.5) | 0.06 |
4th to 5th | 12.9 (9.9–NR) | 4.3 (2.9–11.4) | 5.1 (3.5–9.8) | 5.7 (4.2–7.8) | 0.16 |
Age (years) | |||||
LOT | ≤60 | 61–70 | 71–80 | ≥81 | p-value |
1st to 2nd | 26.8 (23.3–31.3) | 20.0 (16.4–23.7) | 16.0 (14.0–17.7) | 9.7 (6.9–16.5) | <0.000 |
2nd to 3rd | 9.2 (7.6–11.5) | 10.6 (8.6–12.3) | 13.5 (9.8–16.7) | 10.2 (4.2–17.7) | 0.79 |
3rd to 4th | 8.1 (6.21–11.2) | 7.3 (5.4–9.0) | 7.5 (5.4–12.2) | 7.0 (4.24-NR) | 0.35 |
4th to 5th | 5.6 (4.2–8.1) | 5.8 (2.8–10.4) | 5.5 (3.6–10.0) | 9.3 (5.03-NR) | 0.50 |
